Rawdance is piloted by the powerful partnership of co-artistic directors Ryan T. Smith and Wendy Rein. This week, the pair are the sole performers in an evening-length series of duets titled “Double Exposure.” The pieces, each less than five minutes, feature the work of more than a dozen West Coast choreographers. This encore presentation of “Double Exposure,” which premiered to a sold-out theater last year, is on show at ODC Theater in San Francisco from Thursday-Saturday, Oct. 26-28. Smith and Rein add their own duet work to a series of commissioned pieces that draw on various influences, from ballet to butoh, resulting in an athletic, kinetic performance.
NYS Entity Status
NYS Filing Date
APRIL 01, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2013 - DOUBLE EXPOSURE VIP INC
Around the Web
- Rawdance presents a series of duets in ‘Double Exposure’
By Maxine Marshall - Wednesday Oct 25, 2017
- Baidu's Profit More Than Doubles, but Guidance Falls Short
Thursday Oct 26, 2017
Baidu Inc.’s profit more than doubled in the third quarter—helped in part by the sale of its takeout delivery business—but it reported rising expenses as part of its aggressive push into artificial intelligence.
- Retailers Experiment With a New Philosophy: Smaller Is Better
By TIFFANY HSU - Saturday Nov 18, 2017
Department stores and other retailers struggling to beat back e-commerce are taking cues from online start-ups by experimenting with small showrooms.
- Oh … Snap! Teens are coding the future
Wednesday Sep 27, 2017
- Aimmune in Brisbane teams with Regeneron to find peanut allergy cure
By Caroline Chen - Tuesday Oct 17, 2017
Aimmune Therapeutics Inc. is teaming with Regeneron Pharmaceuticals Inc. in hopes of developing a cure for peanut allergies. Aimmune, based in Brisbane, specializes in food allergy treatments and has been developing a desensitizing therapy, AR101, to protect peanut allergy sufferers against reactions from accidental exposures. By combining AR101 with Regeneron’s inflammation-inhibiting drug Dupixent, the companies are seeking to increase protection enough so patients stop reacting to peanuts even after treatment ends. “What we’re learning is that the immune system does seem to be plastic, and with the right group, you can turn the disease back,” Aimmune’s chief executive officer, Stephen Dilly, said.
- Ryder Trucks Launches Campaign With 'Inc.'
Tuesday Sep 19, 2017
"The campaign underscores how truck owners are essentially dumping cash all over America's highways from all the hidden costs required in maintaining a private fleet," Ryder's Karen Jones tells"Marketing Daily."